Relief Therapeutics Holding AG (RLFTF)

[changes_iv]

PW, we need to oust these psychos from the shadows, where they operate, into the light. They’ve done enough damage!

Opinion: 55 years to fulfill a records request? Clearly, the FDA needs serious reform of its data-sharing practices.

https://www.washingtonpost.com/opinions/2021/12/13/55-years-fulfill-records-request-clearly-fda-needs-serious-reform-its-data-sharing-practices/

In my view, that is about to change once Elon Musk gains control over Tweeetr and makes it the peoples public square, no censure!! All other social media or media forms we’ll have their hands full!! No, no ‘good luck wishes’ for those that will try to stop freedom of free speech.

Musk backing off Twitter board opens door to hostile takeover

https://www.cnbc.com/2022/04/11/musk-backing-off-twitter-board-opens-door-to-hostile-takeover.html

In this video, Dr. Naomi Wolf discusses the Volunteer War Room Posse’s raised concerns over the latest batch of Pfizer FDA POIA documents.

Within these documents, we find toxic ingredients within the injection material as well as the allergen Polyethylene Glycol (PEG), which was not disclosed. These ingredients could very well have been the cause of the many adverse reactions experienced by formerly healthy individuals after they received the injections.

https://rumble.com/v1048z7-volunteer-war-room-posse-raise-concerns-over-the-latest-batch-of-pfizer-fda.html

Hindsight has finally arrived, and while still very murky, the fog of Covid is beginning to clear. As a flood of Pfizer documents is released from the FDA, we’ll learn in more detail how 2021 unfolded, who knew what when, and how harmful the vaccines actually are.

The DailyClout/WarRoom Pfizer Document Review team of analysts from medical, statistics, pharmaceutical research, and medical fraud backgrounds, organized by Dr Naomi Wolf, Project Manager Amy Kelly, and the team at DailyClout are studying the documents and sharing their findings with the public as quickly and accurately as possible. There will be a full interim report released in the coming weeks, and they’re also managing to publicize important pieces of information as they emerge. It seems that Pfizer has a recurring theme of keeping highly relevant data to themselves, only to reluctantly publicize it months later. As a quick reminder, they also colluded with the FDA in a failed attempt to continue to conceal this data for our lifetimes.

https://dailyclout.io/pfizer-failed-to-inform-us-about-these-vaccine-health-risks/

JUST IMAGINE INFORMATION LIKE THIS POSTED TO THE MILLIONS IN TWEETR! WE’LL HEAR A SHOUT FOR FREEDOM OF SPEECH AND AVIPTADIL, THE LIKES THE PEOPLE HAVE NEVER HEARD BEFORE!!

The Republicans noted in the letter that Fauci actually touted ZYESAMI as a promising treatment for COVID-19 almost a year ago, but refused to make it widely available until clinical trials were completed.

“The drug remains largely unavailable, and we are told FDA refuses to review the data of NRx’s EUA until the National Institute of Health (NIH) completes clinical trials of ZYESAMI later this year,” they wrote.

Two years into a pandemic and with a death toll exceeding a reported 900,000 Americans, it is unacceptable that the FDA and NIAID are needlessly delaying a treatment for late-stage COVID-19 with a remarkable track record of success. This bureaucratic dragging of your feet appears in stark contrast to the expedited review of other treatments like remdesivir, Molnupiravir, Paxlovid and the COVID-19 vaccines. The FDA’s disparate review processes for different treatments that appears to favor large manufacturers is troubling.

In an interview with Horowitz, Dr. Flavio Cadegiani, a Brazilian endocrinologist who has treated 2,400 COVID patients without losing a single one, explained how the drug fights the virus.

“Aviptadil is a drug that mimics vasoactive intestinal polypeptide (VIP), however, with prolonged effects, compared to the endogenous (produced by the body) VIP,” he said. “VIP and aviptadil act in a type of lung cell called alveolar type II (AT-2), that, although representing just as few as 5% of the cells in the lungs, are largely responsible for oxygen transfer and inhibition of dysfunctional hyper inflammatory reaction and cytokine storm, through the inhibition of the activity of one of the main triggers of these reactions, called NMDA-induced caspase-3.”

Dr. Cadegiani noted that “to date, there is no other molecule capable of working at late stage against COVID-19, and at the same not causing immunosuppression.”

He also believes aviptadil blocks the IL-6, the most dangerous cytokine at the center of the pulmonary dysfunction related to COVID-19. “The importance is that IL-6 is the cytokine that is not effectively blocked by glucocorticoids, even in very high doses. Thus, aviptadil/VIP could confer additional protection when we most need and when we have the fewest resources for.”

He went further to suggest that it is downright malpractice for hospitals not to try this drug at late stage, given the absence of alternatives. “Due to the absence of therapeutic alternatives targeting AT-2 and IL-6, and given the already well-established safety profile, its approval goes beyond the attempt-to-try principle, since it is highly plausible and likely that it works. Therefore, instead of an action of attempt-to-try when giving aviptadil, not providing it when patients fail to respond to other therapies can be considered a medical negligence, from a bioethical perspective.”

https://amgreatness.com/2022/03/09/in-letter-to-fda-and-niaid-ron-johnson-demands-to-know-why-promising-late-stage-covid-drug-was-never-approved/